Pricing and Reimbursement in Russia

DUBLIN, August 15, 2013 /PRNewswire/ --

Research and Markets ( http://www.researchandmarkets.com/research/hp5ql8/pricing_and) has announced the addition of the "Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs through the DLO's Seven Nosologies Program" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The leading business intelligence provider, has released its latest research Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program. It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Russia, with key data, information and analysis of the steps of the pricing and reimbursement process. The report closely scrutinizes major changes in the pharmaceuticals-related pricing and reimbursement in Russia due to the implementation of a new law On Circulation of Drugs.

The scenario of pricing and reimbursement of drugs in Russia is in a dynamic phase. The government of Russia increased the funding of National Healthcare Project to improve the primary healthcare provided to Russians. Under the National Healthcare Project, improvement in primary healthcare, out-patient clinics and technology centres was done.

The launch of the DLO (the acronym for Additional Medicines Supply Program) program was done for disabled persons, pensioners and patients in need of specialized medicines. It was estimated by the Ministry of Health and Social Development that 15 million people will be covered under this program. Since the option of opting for money instead of medicine was provided under the program, a greater number of patients opted for the money. Those patients who opted for medicines got a chance to be treated by some of the best medicines available for their respective therapy areas.

The VZN program (acronym for Seven Nosologies Program) was segmented from the DLO. This was because there is a set of people who need specialized medicines which are particularly expensive. The other segment of the DLO program is called the Essential Drug Program (ONLS). Compulsory medical insurance for all Russians was introduced in 1995. Under the medical insurance plan Russians receive treatment, hospitalization, surgical operation, dental care and other facilities free of charge. However, state medical insurance does not seem to be sufficient for all Russians, so private insurance (voluntary medical insurance) players are also active in the field.

The implementation of the new law on circulation of drugs resulted in the mandatory registration of prices of drugs listed in the Essential Drug List (EDL) in Russia. This means that the Russian government will now regulate the prices of drugs more uniformly. The decision of the Russian government to boost the domestic pharmaceutical market will lead to the launch of more innovative drugs by domestic pharmaceutical companies. Many major global pharmaceutical companies are initiating and expanding their production capacities in Russia to penetrate further into this market.

Scope

- Detailed study of the healthcare scenario in the Russia.

- Analysis of the pricing and reimbursement mechanisms in Russia.

- Key changes that follow from the implementation of new law on circulation of drugs in the pricing and reimbursement system.

- Details about government bodies which regulate different processes of pricing and reimbursement in Russia.

- Details about share of major companies in reimbursement program of Russia.

- Insight into various reimbursement programs in Russia.

For more information visit http://www.researchandmarkets.com/research/hp5ql8/pricing_and

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals